ABCL vs GMED
AbCellera Biologics Inc. vs Globus Medical — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
GMED
Globus Medical
71
Buy
| Metric | ABCL | GMED |
|---|
| AI Score |
66
|
71
|
| Price |
$9.75
|
$85.12
|
| P/E Ratio |
-18.07×
|
21.45×
|
| ROE |
-15.1%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
68.5%
|
| Debt / Equity |
0.15×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
75.9
|
| Beta |
1.191
|
0.954
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus GMED.
GMED leads by 5 points.
GMED scores 71/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical